Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Mike - they’ve read and interpreted the right RNS correctly. This has been a dog of a share, and much too late to the “party”
Wish I had cut my losses earlier
those selling must have read a different rns?
140k down here! Fingers crossed for a strong day!
Excellent, Many thanks Technick, very much appreciated.
Wow, I am so excited right now, even though we are £22k down - paper loss.
GDR are going to deliver Big Time = BUY BUY BUY IMO
Second RNS link (hopefully)
https://polaris.brighterir.com/public/genedrive/news/rns/story/w11m74w/export
@bigAl
https://polaris.brighterir.com/public/genedrive/news/rns/story/w11m74w/export
Can anyone open today's 2nd RNS on Software ? Says page not available ?
Revenue in last 12 months of £1m. Revenue already expected this year of £1m. Hugely significant for the Company.
So not as we would hope for, but we know that people will buy this, and in big volumes.
Hopefully they will continue to build orders and the approvals will just be like turning the tap on!
Yup 11 countries
Great rns
the Genedrive® 96 SARS-CoV-2 Kit achieved 100% sensitivity and 98% specificity in randomised clinical specimens
There will be many comparisons today with other Covid stocks about sales indicative or not, the main difference for me is MCAP, that’s why I will hold and add if it drops 10%
Hi Lp,
I have read so many requests for an update from DB (anything - he owes it too his share holders - he is a crap CEO etc etc). DB has stuck to his promise, when he said on the 12th June ' as a minimum he would update in early July', and he also said that their is an opportunity to update with the Final Fiscal Report - Top Man in my book.
The 1 million projected sales awaiting Country Approvals, does not include the opportunities in the UK -Great News.
Feel really excited for the future. Come on you GDR.
They’ve signed contracts with 11 countries is my understanding
GDR
1mil in sales already
In talks with 11 countries
FDA approval pending
What do people want
Clearly they are two very good updates today removing any concerns that things aren’t progressing. It builds from here.
@bogyo, I don't think the EU is the largest market at the moment as lock downs have reduced the need for testing. Second wave will change that but India and Africa are stallion the exponential rise.
@Scart, agree, there are orders in the pipeline which will support a much higher MC. I think people have to see the 12-month view in order to value GDR correctly. Certainly a lot of upside from current MC in my view.
I wonder why there is no targeting to EU, with a CE mark approval in place. Nothing to wait for here...
Thanks for your reply magsy, from you I’ll take that as a big ramp :-)
Lol top man... initial engagements have immidiately led then to further adapt their offering.
Its lack of understanding not commercial brilliance that's led to new software being developed.
You lot spin anything.
@technick given India is where we think our approvals are most progressed I’m inclined to agree. I doubt many orders are being made until they can see approvals are likely to be given.
A key sentence for me “The Company has received significant interest from customers and distribution partners for this assay and genedrive has now signed additional distribution contracts in respect of 11 countries to work non-exclusively alongside its existing distributor network.”
We’ve got preorders of £1M, which is a good start and once the new distributors sign up following approvals that will imo increase significantly. It won’t be the BOOM first number some were hoping for I’m sure but DB has made it clear that timelines/workloads of countries has slowed down progress in approvals and as I said many I expect are not considering placing orders until they can see approvals are given.
I’m certainly looking forward to the next update that’s for sure! :-)
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it has developed and now CE marked Genedrive® 96 Exporter, a new IVD software module for automated results interpretation of the Genedrive® 96 SARS-CoV-2 Kit. genedrive is one of only a handful of companies offering a full laboratory workflow solution for the analysis of extracted COVID-19 RNA Polymerase Chain Reaction ("PCR") samples, including the test reagents, instrument protocols, and automated analysis software.
The Genedrive® 96 Exporter has been developed to provide further workflow and usability advantages to the Genedrive® 96 SARS-CoV-2 kit. The software module extracts the raw fluorescence run data from third party high throughput real time PCR platforms, analyses the PCR melt-curve data generated using the Genedrive® 96 SARS-CoV-2 Kit. It displays the interpreted data as 'Positive' or 'Negative' in a graphical user interface and as an exportable report. The interpreted data is then available for further inspection on an individual sample, sample group, or entire 96 well plate basis by the user.
The Genedrive® 96 SARS-CoV-2 Kit is a novel CE Marked PCR assay designed to detect active infection in COVID-19 patients. genedrive's one-step PCR bead format eliminates the need for the time consuming and error-prone reagent preparation required in other open-platform test kits. The proprietary format streamlines laboratory workflow, allowing more tests to be performed in a day. During CE-IVD evaluations, the Genedrive® 96 SARS-CoV-2 Kit achieved 100% sensitivity and 98% specificity in randomised clinical specimens.
David Budd, Chief Executive Officer of genedrive plc, said: "The new Genedrive® 96 Exporter software provides a significant improvement to the native software found on third party PCR platforms, allowing for a more seamless workflow for melt curve PCR analysis in COVID-19 PCR testing when using our assay. The tool was developed by repurposing the clinically validated software algorithms we use in our point-of-care Genedrive® instrument software, underscoring the versatility and value in our core technology platform and providing additional differentiation to genedrive's offerings in the COVID-19 testing market.
DB was asked in the Investors Presentation if he knew of any negatives about the PCR test, and DB replied 'NO', but if he had to say anything it would be about the issues with the Software, and he has obviously been working on getting this right -Top man.